Orphan drug development is progressing too slowly

Aims To assess the methodological quality of OMP dossiers and to discuss possible reasons for the small number of products licensed. Methods Information about orphan drug designation and approval was obtained from the website of the European Commission‐Enterprise and Industry DG and from the European Public Assessment Reports. Results Out of 255 OMP designations, only 18 were approved (7.1%). Their dossiers often showed methodological limitations such as inappropriate clinical design, lack of active comparator where available and use of surrogate end‐points. Conclusions The paucity of European incentives for manufacturers and the poor documentation underpinning the applications may have limited the number of new OMP. The over 5000 rare diseases awaiting therapy are an important public health issue.